Table 4.
Causes of death by study arm and for all patients
| Primary Cause of Death | Standard-Dose (n=51) |
High-Dose (n=42) |
All
Patients (n=93) |
|||
|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | |
| Relapse/Progressive disease | 15 | 50.00% | 15 | 53.57% | 30 | 51.72% |
|
| ||||||
| Non-relapse mortality | 12 | 40.00% | 10 | 35.71% | 22 | 37.93% |
| Infection | 5 | 2 | 7 | |||
| Second primary malignancy | 5 | 6 | 11 | |||
| Other | 2 | 2 | 4 | |||
|
| ||||||
| Unknown* | 3 | 10.00% | 3 | 10.71% | 6 | 10.35% |
|
| ||||||
| Total | 30 | 100.00% | 28 | 100 | 58 | 100.00% |
Abbreviations: No., number of deaths per study arm; %, percentage of deaths per total per study arm.
*
For the unknown causes of death, the primary cause of death was not documented. However, one patient in the standard-rituximab group and two patients in the high-dose rituximab group had progressive disease at time of death, and all others with no evidence of disease.